Combination treatment of ocular inflammatory disorders and diseases

An inflammatory disease, ocular technology, applied in the field of combined treatment of ocular inflammatory diseases and diseases, can solve the problems of complex immunomodulators and other issues

Pending Publication Date: 2019-01-04
ALDEYRA THERAPEUTICS
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, use of steroids and other immunomodulators is complicated by severe and numerous side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination treatment of ocular inflammatory disorders and diseases
  • Combination treatment of ocular inflammatory disorders and diseases
  • Combination treatment of ocular inflammatory disorders and diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0160] Example 1: Randomized, Investigator-masked comparator-controlled trial of NS2 compound eye drops in patients with anterior uveitis

[0161] Uveitis is inflammation of the eye involving structures in the uvea, such as the iris, ciliary body, and choroid. Specifically, anterior uveitis refers to uveitis in the anterior segment of the eye. It can also involve the posterior segment of the eye or the entire eye (panuveitis). Clinical signs and symptoms of anterior uveitis may include pain, blurred vision, conjunctival skin injection, anterior chamber cells, anterior chamber flare, fibrin deposits, and corneal endothelial inflammatory deposits. Uveitis is not a single disease entity, but a form of ocular inflammation associated with multiple groups of infectious and noninfectious conditions.

[0162] NS2 is a novel aldehyde scavenger formulated for this study as topical eye drops. Accumulation of toxic aldehyde metabolites such as malondialdehyde (MDA) is associated with a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 333,549, filed May 9, 2016, the contents of which are hereby incorporated by reference in their entirety. Background technique [0003] Eye inflammation can manifest as a number of ocular conditions of varying severity depending on the location of the inflammation. Conditions attributed to ocular inflammation include uveitis, allergic conjunctivitis, scleritis, optic neuritis, keratitis, and the like. Eye inflammation has many causes ranging from autoimmune disorders, environmental irritants and injuries such as surgery. Some forms of eye inflammation are secondary to bacterial or viral infection, and some eye inflammation has no known cause. Symptoms may include eye pain, red eyes, photophobia, floaters, vision loss, or a combination of these symptoms. [0004] Uveitis is typical of these ocular inflammatory disorders ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/47A61K9/00A61P27/02
CPCA61K45/06A61K31/436A61K31/165A61K31/192A61K31/196A61K31/519A61K31/573A61K9/0048A61K9/08A61K31/47A61P27/02A61P29/00A61K2300/00A61K47/40
Inventor 托德·布雷迪斯科特·杨
Owner ALDEYRA THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap